PL3512517T3 - Stosowanie pridopidyny w leczeniu lęku i depresji - Google Patents

Stosowanie pridopidyny w leczeniu lęku i depresji

Info

Publication number
PL3512517T3
PL3512517T3 PL17851619.1T PL17851619T PL3512517T3 PL 3512517 T3 PL3512517 T3 PL 3512517T3 PL 17851619 T PL17851619 T PL 17851619T PL 3512517 T3 PL3512517 T3 PL 3512517T3
Authority
PL
Poland
Prior art keywords
pridopidine
anxiety
depression
treatment
Prior art date
Application number
PL17851619.1T
Other languages
English (en)
Inventor
Michael Hayden
Mahmoud Abdulhossein Pouladi
Original Assignee
Prilenia Neurotherapeutics Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd. filed Critical Prilenia Neurotherapeutics Ltd.
Publication of PL3512517T3 publication Critical patent/PL3512517T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL17851619.1T 2016-09-15 2017-09-15 Stosowanie pridopidyny w leczeniu lęku i depresji PL3512517T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662395259P 2016-09-15 2016-09-15
US201762532728P 2017-07-14 2017-07-14
PCT/US2017/051814 WO2018053287A1 (en) 2016-09-15 2017-09-15 Use of pridopidine for the treatment of anxiety and depression

Publications (1)

Publication Number Publication Date
PL3512517T3 true PL3512517T3 (pl) 2025-09-08

Family

ID=61618951

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17851619.1T PL3512517T3 (pl) 2016-09-15 2017-09-15 Stosowanie pridopidyny w leczeniu lęku i depresji

Country Status (11)

Country Link
US (1) US20200375966A1 (pl)
EP (1) EP3512517B8 (pl)
JP (2) JP2019529411A (pl)
CN (1) CN109952100A (pl)
AU (2) AU2017326436A1 (pl)
CA (1) CA3036842A1 (pl)
DK (1) DK3512517T3 (pl)
ES (1) ES3031271T3 (pl)
IL (2) IL265356A (pl)
PL (1) PL3512517T3 (pl)
WO (1) WO2018053287A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG188298A1 (en) 2010-09-03 2013-04-30 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
PE20160195A1 (es) 2013-06-21 2016-05-14 Teva Pharmaceuticals Int Gmbh Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
WO2018039475A1 (en) 2016-08-24 2018-03-01 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating dystonias
ES3025836T3 (en) 2016-08-24 2025-06-09 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating functional decline
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
CA3050700C (en) 2017-01-20 2023-10-03 Prilenia Neurotherapeutics Ltd. Use of pridopidine for the treatment of fragile x syndrome
AU2018329628B2 (en) 2017-09-08 2021-04-22 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
EP3920924A4 (en) 2019-02-04 2022-11-16 Prilenia Neurotherapeutics Ltd. LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES
CN112921100A (zh) * 2019-12-06 2021-06-08 宁波海尔施基因科技有限公司 一种检测人类压力敏感度基因型的试剂盒和方法
MX2023004516A (es) * 2020-10-20 2023-05-04 Prilenia Neurotherapeutics Ltd Uso de pridopidina y analogos para el tratamiento de la ansiedad y la depresion.
WO2022219637A1 (en) * 2021-04-14 2022-10-20 Prilenia Neurotherapeutics Ltd. Treatment of prodromal huntington disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
CA2584831C (en) 2004-10-13 2013-09-17 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
SG188298A1 (en) 2010-09-03 2013-04-30 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
PE20160195A1 (es) 2013-06-21 2016-05-14 Teva Pharmaceuticals Int Gmbh Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
WO2015179522A1 (en) * 2014-05-21 2015-11-26 Akili Interactive Labs, Inc. Processor-implemented systems and methods for enhancing cognitive abilities by personalizing cognitive training regimens
WO2016138135A1 (en) * 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
EP4282479A3 (en) * 2015-02-25 2024-02-21 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety

Also Published As

Publication number Publication date
EP3512517B8 (en) 2025-04-23
CN109952100A (zh) 2019-06-28
EP3512517A1 (en) 2019-07-24
CA3036842A1 (en) 2018-03-22
JP2019529411A (ja) 2019-10-17
ES3031271T3 (en) 2025-07-07
IL265356A (en) 2019-05-30
US20200375966A1 (en) 2020-12-03
EP3512517B1 (en) 2025-03-19
IL290754A (en) 2022-04-01
WO2018053287A1 (en) 2018-03-22
DK3512517T3 (da) 2025-06-10
AU2021200697A1 (en) 2021-03-04
AU2017326436A1 (en) 2019-04-11
JP2022062047A (ja) 2022-04-19
EP3512517A4 (en) 2020-05-06

Similar Documents

Publication Publication Date Title
PL3512517T3 (pl) Stosowanie pridopidyny w leczeniu lęku i depresji
IL279752B (en) Polycyclic compounds and use thereof in the treatment of immune disorders
IL286888A (en) Use of pridopidine to treat depression or anxiety
IL283086A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
IL262092A (en) Humanized anti-pacap antibodies and uses thereof
SI3436048T1 (sl) Neoantigeni in načini uporabe
PL4272834T3 (pl) Zastosowanie terapeutyczne mitochondriów i połączonych środków mitochondrialnych
HUE054548T2 (hu) Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
SI3402888T1 (sl) Sredstva in metode za zdravljenje HBV
HRP20260151T1 (hr) Modificirani polipeptidi i njihova uporaba
SI3368069T1 (sl) Uporaba zaviralcev miostatina in kombinirane terapije
SI3240554T1 (sl) Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni
SI3258951T1 (sl) Anti-pvrig protitelesa in metode uporabe
PL3503890T3 (pl) Stosowanie pridopidyny w leczeniu dystonii
BR112015022854A2 (pt) pró-farmacos de fumaratos e uso do mesmo no tratamento de várias doenças
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
HUE065152T2 (hu) Fluor-fenil-béta-hidroxietilaminok és alkalmazásuk hiperglikémia kezelésében
PL3493812T3 (pl) Połączenia imetelstatu i wenetoklaksu do leczenia ostrej białaczki szpikowej
PL3229794T3 (pl) Kombinacja farmaceutyczna obejmująca ponesimod i jej zastosowanie w leczeniu stwardnienia rozsianego
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
PL3732294T3 (pl) Tymohydrochinon do stosowania w leczeniu hiperglikemii
HUE045025T2 (hu) Heterobiciklusos vegyületek és alkalmazásuk tuberkulózis kezelésére
PL3592355T3 (pl) Kx2-391/kx-01 do zastosowania w leczeniu rogowacenia słonecznego
IL271464A (en) Nk-1 antagonist compositions and methods for use in treating depression
IL270978B (en) Grape skin for use in the treatment of dysbiosis